Search Results
Found 1 results
510(k) Data Aggregation
(1073 days)
Field Shield Wound Dressing
Rx
Management of partial and full thickness wounds including stage I - IV pressure ulcers, ulcers caused by mixed vascular etiologies, Diabetic skin ulcers, 1st and 2nd degree burns, post-surgical incisions, graft sites, lacerations, skin tears, cuts and abrasions.
OTC
Management of minor wounds including minor cuts, abrasions, lacerations and burns.
The Field Shield Wound Dressing is a spray on hydrogel wound dressing that hydrates, seals and protects dermal injuries to create and maintain a moist wound environment. A moist wound environment is known to be conducive to the wound healing process. It is a hydrophilic system containing a polyacrylate polymer matrix with silver hydrosol and lidocaine. The dressing donates moisture to a wound and maintains a moist environment. When applied to the liquid device donates moisture to the wound then sets into a thin, pliable, transparent film barrier over the surface of the wound. The film is capable of setting over intact and compromised skin surfaces. The device is intended for use for up to 30 days. with reapplication recommended every 24 to 72 hours. The device contains silver hydrosol that may inhibit the growth of microorganisms such as Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant strains of MRSA and VRE, as well as fungi such as Candida albicans and Candida auris within the dressing. Additionally, the dressing contains lidocaine as a topical anesthetic. Clinical evaluation showed that the Lidocaine can reduce pain within 30 minutes after application; long-term pain reduction has not been evaluated. Field Shield® Wound Dressing is intended for both Prescription and over the counter (OTC) indications for use.
The provided document describes the KeriCure Inc.'s Field Shield Wound Dressing, an unclassified device. The information focuses on demonstrating its substantial equivalence to predicate devices, particularly regarding safety and effectiveness.
Here's an analysis of the acceptance criteria and the study that proves the device meets them:
1. Table of Acceptance Criteria and Reported Device Performance
The acceptance criteria are not explicitly stated as quantitative thresholds for the Field Shield Wound Dressing. Instead, the document focuses on demonstrating that the device meets safety and performance standards equivalent to predicate devices, particularly through various types of testing. The reported device performance is outlined in the "Summary of Performance Testing" table.
Test Type | Acceptance Criteria (Implied by "Passed") | Reported Device Performance (Results) |
---|---|---|
Clinical Study (Pain Relief) | Significant reduction in pain | Pain Relief provided within 30 minutes of application. The lidocaine within the device has a biological effect on the skin or wound, providing a significant reduction in pain to the treatment area when applied via spray within 30 minutes of application. |
Biocompatibility (Guinea Pig Maximization Sensitization Test) | No sensitization | Passed (Score 0) |
Biocompatibility (Irritation Test) | No irritation | Passed (Score 0) |
Biocompatibility (Acute Systemic Toxicity) | Non-toxic | Passed (Non-toxic) |
Biocompatibility (Material Mediated Pyrogenicity Test) | Non-pyrogenic | Passed |
Biocompatibility (Subacute/Subchronic Toxicity) | No significant toxicity | Passed |
Biocompatibility (Implantation) | No adverse effects | Passed |
Antimicrobial Preservative Effectiveness (USP) | Meet USP 51 and PCPC requirements | Passed (met USP 51 and PCPC requirements) |
Antimicrobial (USP Modified "Time to Kill" Test) | 99.99% reduction of microorganisms | Passed, 99.99% Reduction within 10 minutes of microorganisms including Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, antibiotic resistant strains of MRSA and VRE, as well as fungi such as Candida albicans and Candida auris. |
Endotoxin Analysis | Below specified limits | Passed, |
Ask a specific question about this device
Page 1 of 1